Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Announces Earnings Results

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) announced its earnings results on Monday. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.62 by $0.04, Zacks reports. The company had revenue of $5.55 billion during the quarter, compared to analysts’ expectations of $5.49 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.88% and a return on equity of 8.90%.

Fresenius Medical Care AG & Co. KGaA Stock Down 6.1%

FMS stock traded down $1.55 during trading hours on Tuesday, hitting $23.71. The company’s stock had a trading volume of 586,662 shares, compared to its average volume of 677,354. The stock has a 50 day moving average price of $23.39 and a two-hundred day moving average price of $22.96. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $20.02 and a 12 month high of $27.64. The company has a market capitalization of $12.74 billion, a PE ratio of 12.38, a price-to-earnings-growth ratio of 4.56 and a beta of 0.77. The company has a quick ratio of 0.86, a current ratio of 1.20 and a debt-to-equity ratio of 0.40.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on FMS. Zacks Research raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, May 6th. Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings cut Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Finally, Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th. Six investment analysts have rated the stock with a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $23.95.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Morgan Stanley raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% in the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after purchasing an additional 942,497 shares during the period. Integral Health Asset Management LLC raised its holdings in Fresenius Medical Care AG & Co. KGaA by 44.4% in the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after acquiring an additional 200,000 shares during the period. Bank of America Corp DE lifted its position in Fresenius Medical Care AG & Co. KGaA by 279.7% during the 2nd quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock worth $9,637,000 after acquiring an additional 248,477 shares during the last quarter. Millennium Management LLC grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 2.8% in the third quarter. Millennium Management LLC now owns 317,109 shares of the company’s stock valued at $8,349,000 after purchasing an additional 8,719 shares during the last quarter. Finally, Raymond James Financial Inc. increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 1.5% in the third quarter. Raymond James Financial Inc. now owns 282,074 shares of the company’s stock worth $7,427,000 after purchasing an additional 4,079 shares during the period. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.